BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Itovebi (Inavolisib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Itovebi (Inavolisib)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07245797-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07245797)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Phase
  II\, Multicenter\, Open-label Study to Evaluate the Efficacy and Safety o
 f Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as S
 ubcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated
 \, HER2+\, eBC\nEstimated primary completion: 15 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Itovebi (Inavolisib): Phase 1 readout est. (NCT03006172)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: To Evaluate the Safety\, Tolerability\, and Pharmacokinetics
  of Inavolisib Single Agent in Participants With Solid Tumors and in Combi
 nation With Endocrine and Targeted Therapies in Participants With Breast C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03006172
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05306041-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05306041)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: Neoadju
 vant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+\, HR+\, 
 PIK3CA Mutant Early Breast Cancer\nEstimated primary completion: January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05306041
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894239-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT05894239)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, Breast Cancer.\nStudy: A Study
  to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phe
 sgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-
 Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer\nEstima
 ted primary completion: 3 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05894239
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496568-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Itovebi (Inavolisib): Phase 1 readout est. (NCT06496568)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1.\nStudy: A Study Evaluating Sing
 le-agent Inavolisib\, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cance
 rs\nEstimated primary completion: 21 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06496568
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904208-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Itovebi (Inavolisib): Phase 1 readout est. (NCT07904208)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1.\nStudy: Oral GDC-0077 in Premat
 ure Ovarian Insufficiency\nEstimated primary completion: 30 July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07904208
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07054190)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Study
  to Test Inavolisib Treatments in Participants With Early-Stage\, PIK3CA-M
 utated Breast Cancer\nEstimated primary completion: 31 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04449874-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Itovebi (Inavolisib): Phase 1 readout est. (NCT04449874)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1.\nStudy: A Study to Evaluate the
  Safety\, Pharmacokinetics\, and Activity of GDC-6036 Alone or in Combinat
 ion in Participants With Advanced or Metastatic Solid Tumors With a KRAS G
 12C Mutation\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04449874
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT04931342)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: A Study Evaluating the 
 Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persist
 ent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary complet
 ion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/inavolisib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04931342
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441512-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07441512)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Phase
  II\, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib i
 n Combination With Eribulin in Pretreated Advanced Triple-negative Breast 
 Cancer Harboring a PIK3CA Mutation\nEstimated primary completion: 15 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0744151
 2
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287150-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07287150)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: A Study to Test Inavoli
 sib Treatment in Participants With Metastatic Castration-Resistant Prostat
 e Cancer\nEstimated primary completion: 31 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07287150
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694973-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20280629
DTEND;VALUE=DATE:20280630
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07694973)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: A Multicenter\, Single 
 Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavo
 lisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients\nEst
 imated primary completion: 29 June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07694973
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05708235)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring M
 RD Using ctDNA in HR-positive/HER2-negative EBC Population\nEstimated prim
 ary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05708235
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368998-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07368998)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: To Study the Effect of Inavolisib in Combination With Fulves
 trant in Participants With Breast Cancer\nEstimated primary completion: 31
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavol
 isib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07368998
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07618390)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Phase ll\, Interventional\, Single-arm Study Evaluating th
 e Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chi
 nese Patients With PIK3CA-mutant\, HR-positive\, HER2-negative Locally Adv
 anced or Metastatic Breast Cancer.\nEstimated primary completion: December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761839
 0
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405801-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07405801)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Phase II Study Evaluating the Efficacy and Safety of Inavo
 lisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus
  Fulvestrant in Participants With Advanced Breast Cancer\nEstimated primar
 y completion: 19 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07405801
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Itovebi (Inavolisib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tre
 atment Combinations in Participants With Breast Cancer\nEstimated primary 
 completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/inavolisib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04802759
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestrant 
 With or Without Palbociclib in Participants With Advanced Breast Cancer (A
 BC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT05332561)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: Genomic
 s Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast C
 ancer (COGNITION-GUIDE)\nEstimated primary completion: March 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522697-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07522697)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: Inavolisib for PIK3CA M
 utated Advanced Endometrial Cancer: MITO END-4\nEstimated primary completi
 on: May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavoli
 sib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07522697
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929223-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Itovebi (Inavolisib): Phase 1 readout est. (NCT04929223)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1.\nStudy: A Study Evaluating the 
 Safety and Efficacy of Targeted Therapies in Subpopulations of Patients Wi
 th Metastatic Colorectal Cancer (INTRINSIC)\nEstimated primary completion:
  31 August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inav
 olisib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04929223
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Itovebi (Inavolisib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Itovebi (Inavolisib)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tre
 atment Combinations in Patients With Metastatic or Locally Advanced Breast
  Cancer\nEstimated primary completion: 30 September 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790693-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT06790693)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Efficacy and Safety of Inavolisib Plu
 s CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Par
 ticipants With Endocrine-Sensitive PIK3CA-Mutated\, Hormone Receptor-Posit
 ive\, HER2-Negative Advanced Breast Cancer\nEstimated primary completion: 
 31 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inav
 olisib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06790693
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT04589845)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: Tumor-agnostic Precisio
 n Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platfo
 rm Study\nEstimated primary completion: 25 September 2032. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-2545@assetmemo.bio
DTSTAMP:20261121T004459Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT05862285)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3.\nStudy: A Rollover Study for Pa
 rticipants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche S
 ponsored Study\nEstimated primary completion: 1 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
